Upstream Bio, Inc. (UPB) income statement
UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$2.08−0.02 (-0.95%)
Close on Nov 18, 2026Market cap $113.92MP/E –Yield –
Upstream Bio, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -6116.0%
- Net margin
- -5712.3%
- Return on equity, FY2025
- -35.4%
Financial strength
- Current ratio
- 20.45
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 396.5%
Valuation
- P/E ratio
- –
- Price to sales
- 39.69
- Price to book
- 0.49
- Dividend yield
- –
See a number that looks wrong?